Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan
- PMID: 10731446
- DOI: 10.1006/jmcc.1999.1093
Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan
Abstract
Levosimendan, an inodilatory drug discovered using troponin C as a target protein, has a cardiac effect deriving from the calcium sensitization of contractile proteins. The aim of this study was to give further evidence that levosimendan binds to cardiac troponin C and that the binding involves amino acid residues on helixepsilon of the N-terminal domain of this calcium-binding protein. Nine organic molecules, obtained by chemical modification of levosimendan, were tested both for their calcium-dependent binding to troponin C and troponin complex affinity HPLC columns, and for their ability to increase the calcium sensitivity of myofilaments in cardiac skinned fibers. A good correlation between the calcium sensitization and the calcium-dependent binding to troponin complex (r=0.90) and to cardiac troponin C (r=0.91) for the analogs of levosimendan was shown. In addition, the effect of levosimendan on the calcium-induced conformational changes in native and point-mutated cTnC was studied. Cys84-->Ser, Asp87-->Lys and Asp88-->Ala point-mutated cTnC were shown to maintain a high affinity to calcium, but their Ca(2+)titration curves were not influenced by levosimendan as for the native protein. Finally, it was demonstrated that the NMR chemical shifts of the terminal methyl groups of Met47, Met81, and Met85 on calcium-saturated cTnC were changed after addition of levosimendan in water solution at pH 7.4. This effect was not seen when adding an analog of levosimendan, which did not bind to the troponin C affinity HPLC column and did not increase the calcium-induced tension in cardiac skinned fibers.
Copyright 2000 Academic Press.
Similar articles
-
The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.Mol Cell Biochem. 2004 Nov;266(1-2):87-107. doi: 10.1023/b:mcbi.0000049141.37823.19. Mol Cell Biochem. 2004. PMID: 15646030 Review.
-
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.J Biol Chem. 2001 Mar 23;276(12):9337-43. doi: 10.1074/jbc.M007484200. Epub 2000 Dec 11. J Biol Chem. 2001. PMID: 11113122
-
Mechanisms of action of calcium-sensitizing drugs.J Cardiovasc Pharmacol. 1995;26 Suppl 1:S10-9. J Cardiovasc Pharmacol. 1995. PMID: 8907127 Review.
-
Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides.J Mol Cell Cardiol. 2003 Sep;35(9):1055-61. doi: 10.1016/s0022-2828(03)00178-0. J Mol Cell Cardiol. 2003. PMID: 12967628
-
Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan.J Mol Cell Cardiol. 1995 Sep;27(9):1859-66. doi: 10.1016/0022-2828(95)90009-8. J Mol Cell Cardiol. 1995. PMID: 8523447
Cited by
-
Future pharmacologic agents for treatment of heart failure in children.Pediatr Cardiol. 2006 Sep-Oct;27(5):533-51. doi: 10.1007/s00246-006-1289-0. Epub 2006 Aug 23. Pediatr Cardiol. 2006. PMID: 16933064 Review.
-
The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.Mol Cell Biochem. 2004 Nov;266(1-2):87-107. doi: 10.1023/b:mcbi.0000049141.37823.19. Mol Cell Biochem. 2004. PMID: 15646030 Review.
-
General Critical Care, Temperature Control, and End-of-Life Decision Making in Patients Resuscitated from Cardiac Arrest.J Clin Med. 2023 Jun 18;12(12):4118. doi: 10.3390/jcm12124118. J Clin Med. 2023. PMID: 37373812 Free PMC article. Review.
-
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.J Cardiovasc Pharmacol. 2020 Jul;76(1):4-22. doi: 10.1097/FJC.0000000000000859. J Cardiovasc Pharmacol. 2020. PMID: 32639325 Free PMC article. Review.
-
Multiorgan Drug Action of Levosimendan in Critical Illnesses.Biomed Res Int. 2019 Sep 19;2019:9731467. doi: 10.1155/2019/9731467. eCollection 2019. Biomed Res Int. 2019. PMID: 31641670 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous